Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranexa NDA Amendment Seeks Restricted Angina Indication

This article was originally published in The Pink Sheet Daily

Executive Summary

CV Therapeutics' complete response to FDA's October 2003 "approvable" letter is based on the ERICA trial in patients refractory to the maximum labeled dose of Pfizer's calcium channel blocker Norvasc.

You may also be interested in...



CV Therapeutics Pulls Ranexa Marketing Application In Europe

The firm says it plans to resubmit the application for the chronic angina therapy upon completing “one or several” pharmacokinetic studies.

CV Therapeutics Pulls Ranexa Marketing Application In Europe

The firm says it plans to resubmit the application for the chronic angina therapy upon completing “one or several” pharmacokinetic studies.

Aceon Gets Coronary Artery Disease Approval Ahead Of Schedule

Aceon adds indication for reduction of risk of cardiovascular mortality and non-fatal myocardial infarction in patients with stable coronary artery disease ahead of Sept. 10 user fee date.

Topics

UsernamePublicRestriction

Register

ID1132028

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel